Anika Therapeutics Inc Cash Flow Conversion Efficiency
Anika Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Anika Therapeutics Inc (ANIK) has a cash flow conversion efficiency ratio of -0.005x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-684.00K) by net assets ($137.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Anika Therapeutics Inc (1993–2025)
Cash flow conversion efficiency of Anika Therapeutics Inc from 1993 to 2025. This chart illustrates how Anika Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Anika Therapeutics Inc stock quote for real-time trading data and today's change.
Anika Therapeutics Inc Cash Flow Conversion Ratio Explained
Anika Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Anika Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anika Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Anika Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perimeter Acquisition Corp. I Class A Ordinary Shares
NASDAQ:PMTR
|
0.000x |
|
CERRO DE PASCO RES
F:N8HP
|
-0.043x |
|
Vogenx Inc Common Stock
NASDAQ:VOGX
|
-0.015x |
|
NEXCOM International Co Ltd
TWO:8234
|
0.017x |
|
Daedalus Special Acquisition Corp.
NASDAQ:DSAC
|
-0.001x |
|
Zhejiang Yaguang Technology Co. Ltd. A
SHG:603282
|
N/A |
|
BIDV Securities JSC
VN:BSI
|
0.055x |
|
Brompton Split Banc Corp
TO:SBC
|
0.008x |
Annual Cash Flow Conversion Efficiency for Anika Therapeutics Inc (1993–2025)
The table below shows the annual cash flow conversion efficiency of Anika Therapeutics Inc from 1993 to 2025. Review how much free cash does Anika Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $143.47 Million | $11.19 Million | 0.078x | +122.26% |
| 2024-12-31 | $153.99 Million | $5.40 Million | 0.035x | +516.54% |
| 2023-12-31 | $212.26 Million | $-1.79 Million | -0.008x | -154.56% |
| 2022-12-31 | $285.56 Million | $4.41 Million | 0.015x | -47.21% |
| 2021-12-31 | $287.08 Million | $8.40 Million | 0.029x | -39.02% |
| 2020-12-31 | $272.40 Million | $13.06 Million | 0.048x | -62.62% |
| 2019-12-31 | $288.38 Million | $37.01 Million | 0.128x | -3.12% |
| 2018-12-31 | $263.61 Million | $34.92 Million | 0.132x | -14.48% |
| 2017-12-31 | $263.49 Million | $40.81 Million | 0.155x | +44.97% |
| 2016-12-31 | $222.77 Million | $23.80 Million | 0.107x | -42.33% |
| 2015-12-31 | $210.85 Million | $39.06 Million | 0.185x | -17.46% |
| 2014-12-31 | $178.10 Million | $39.98 Million | 0.224x | +20.99% |
| 2013-12-31 | $135.63 Million | $25.16 Million | 0.186x | +91.58% |
| 2012-12-31 | $108.93 Million | $10.55 Million | 0.097x | -9.79% |
| 2011-12-31 | $94.76 Million | $10.17 Million | 0.107x | +16.45% |
| 2010-12-31 | $85.19 Million | $7.85 Million | 0.092x | +144.70% |
| 2009-12-31 | $82.14 Million | $3.09 Million | 0.038x | -32.82% |
| 2008-12-31 | $60.76 Million | $3.41 Million | 0.056x | -31.39% |
| 2007-12-31 | $54.96 Million | $4.49 Million | 0.082x | +85.81% |
| 2006-12-31 | $45.49 Million | $2.00 Million | 0.044x | -74.16% |
| 2005-12-31 | $37.89 Million | $6.45 Million | 0.170x | -78.30% |
| 2004-12-31 | $30.36 Million | $23.82 Million | 0.785x | +601.34% |
| 2003-12-31 | $17.98 Million | $2.01 Million | 0.112x | +474.96% |
| 2002-12-31 | $17.06 Million | $332.03K | 0.019x | +109.07% |
| 2001-12-31 | $20.10 Million | $-4.31 Million | -0.215x | -204.37% |
| 2000-12-31 | $26.71 Million | $-1.88 Million | -0.071x | -326.50% |
| 1999-12-31 | $25.70 Million | $800.00K | 0.031x | -72.63% |
| 1998-12-31 | $29.90 Million | $3.40 Million | 0.114x | +14.59% |
| 1997-12-31 | $26.20 Million | $2.60 Million | 0.099x | +145.11% |
| 1996-12-31 | $5.00 Million | $-1.10 Million | -0.220x | +24.94% |
| 1995-12-31 | $5.80 Million | $-1.70 Million | -0.293x | +34.05% |
| 1994-12-31 | $5.40 Million | $-2.40 Million | -0.444x | -495.56% |
| 1993-12-31 | $6.70 Million | $-500.00K | -0.075x | -- |
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more